The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
U.S. Acute Care Solutions
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
myHomecare Group
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advising Australian Unity on its acquisition of myHomecare Group
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Slayback Pharma LLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Interest in Joint Venture with CarepathRx Health System Solutions
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Clinigen Ltd’s Proleukin
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
GI Alliance
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Theramex
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Acacia Pharma Group plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Alteon Health
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
![Colombia Colombia flag](https://www.greenhill.com/sites/default/files/colombia-flag.png)
Procaps Group
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Faes Farma, flagship product Bilastine
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
VEP Healthcare
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
MindPath Care Centers
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
MDLIVE
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Acacia Pharma Group plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
US Acute Care Solutions
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Biogix, Inc.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Akorn, Inc.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Surgery Partners’ Anesthesia Services
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
340B Link
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Cello Health plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
![Denmark Denmark flag](https://www.greenhill.com/sites/default/files/denmark_flag%5B1%5D.gif)
Global collaboration agreement with Genmab A/S
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Cerner RevWorks
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services
![](https://www.greenhill.com/sites/default/files/lang-ca-us.png)
Abacus Health Products, Inc.
![](https://www.greenhill.com/sites/default/files/lang-ca-us.png)
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
OurHealth
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised OurHealth, a provider of onsite and near-site employer-sponsored primary care clinics, on its sale to General Atlantic and merger with Marathon Health
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Pfizer Inc. Consumer Health Business
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Starpharma Holdings Limited, patented VivaGel BV® product
![Italy, USA flags](https://www.greenhill.com/sites/default/files/italian-us-flag.png)
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Aisthesis
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Montserrat Day Hospital Group
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Common shares and common share purchase warrants in Canopy Growth
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Concordia International Corp.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Derma Sciences, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Palatin Technologies, Inc. lead product candidate, Rekynda
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
![USA/Canada U.S.A., Canada flags](https://www.greenhill.com/sites/default/files/usa_canada.gif)
Concordia International Corp
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
![UK/Ireland U.K., Ireland flags](https://www.greenhill.com/sites/default/files/uk-ireland_35558.gif)
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Limited
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
BioD, LLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to an authorized generic version of Adderall XR
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 37 approved and 5 pipeline generic products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Aegerion Pharmaceuticals
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Total Care Medicaid Plan
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Boehringer Ingelheim
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Aesynt, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Allergan Generics
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Altegra Health, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Portfolio of GlaxoSmithKline plc consumer and OTC brands
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Refinancing of syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
MannKind Corporation
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
![USA/Germany U.S.A., Germany flags](https://www.greenhill.com/sites/default/files/usa_germany.gif)
Siemens Health Services
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Clinuvel Pharmaceuticals Limited
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Forest Laboratories Inc.
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Unfors Raysafe AB
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Fidelis SeniorCare Inc. (Michigan Heath Plan)
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Warner Chilcott, plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Coventry Health Care Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
ISTA Pharmaceuticals, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
iNova Pharmaceuticals
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
American Dental Partners, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
![Japan Japan flag](https://www.greenhill.com/sites/default/files/japan.gif)
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
![USA/Switzerland U.S.A., Swiss flags](https://www.greenhill.com/sites/default/files/usa_swiss.gif)
Alcon, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Medicity, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Healthcare Australia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Taro Pharmaceutical Industries
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Breast Care Business of Ethicon-Endo Surgery
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Medegen, Inc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Heartscape Technologies, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Enzon Pharmaceuticals, Inc.
![Italy Italy flag](https://www.greenhill.com/sites/default/files/italy.gif)
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Monogram Biosciences, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Genentech, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Applied Biosystems Group
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Ventana Medical Systems, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Cardinal Health, Inc., Pharmaceutical Technologies and Services division
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Kos Pharmaceuticals, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories